全文获取类型
收费全文 | 16140篇 |
免费 | 1119篇 |
国内免费 | 41篇 |
专业分类
耳鼻咽喉 | 256篇 |
儿科学 | 483篇 |
妇产科学 | 398篇 |
基础医学 | 1918篇 |
口腔科学 | 289篇 |
临床医学 | 1659篇 |
内科学 | 3165篇 |
皮肤病学 | 117篇 |
神经病学 | 1287篇 |
特种医学 | 650篇 |
外科学 | 2577篇 |
综合类 | 266篇 |
一般理论 | 13篇 |
预防医学 | 1332篇 |
眼科学 | 1074篇 |
药学 | 822篇 |
中国医学 | 20篇 |
肿瘤学 | 974篇 |
出版年
2023年 | 89篇 |
2022年 | 201篇 |
2021年 | 420篇 |
2020年 | 198篇 |
2019年 | 283篇 |
2018年 | 410篇 |
2017年 | 298篇 |
2016年 | 312篇 |
2015年 | 412篇 |
2014年 | 542篇 |
2013年 | 764篇 |
2012年 | 1153篇 |
2011年 | 1193篇 |
2010年 | 670篇 |
2009年 | 594篇 |
2008年 | 1036篇 |
2007年 | 1038篇 |
2006年 | 1025篇 |
2005年 | 1018篇 |
2004年 | 955篇 |
2003年 | 874篇 |
2002年 | 858篇 |
2001年 | 185篇 |
2000年 | 132篇 |
1999年 | 185篇 |
1998年 | 164篇 |
1997年 | 145篇 |
1996年 | 109篇 |
1995年 | 111篇 |
1994年 | 106篇 |
1993年 | 95篇 |
1992年 | 105篇 |
1991年 | 92篇 |
1990年 | 97篇 |
1989年 | 96篇 |
1988年 | 81篇 |
1987年 | 92篇 |
1986年 | 68篇 |
1985年 | 85篇 |
1984年 | 100篇 |
1983年 | 83篇 |
1982年 | 93篇 |
1981年 | 121篇 |
1980年 | 89篇 |
1979年 | 57篇 |
1978年 | 52篇 |
1977年 | 38篇 |
1976年 | 44篇 |
1975年 | 36篇 |
1974年 | 32篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
131.
132.
133.
Isaac Snowhite Ricardo Pastori Jay Sosenko Shari Messinger Cayetano Alberto Pugliese 《Diabetes》2021,70(2):638
Type 1 diabetes is an autoimmune disease resulting in severely impaired insulin secretion. We investigated whether circulating microRNAs (miRNAs) are associated with residual insulin secretion at diagnosis and predict the severity of its future decline. We studied 53 newly diagnosed subjects enrolled in placebo groups of TrialNet clinical trials. We measured serum levels of 2,083 miRNAs, using RNA sequencing technology, in fasting samples from the baseline visit (<100 days from diagnosis), during which residual insulin secretion was measured with a mixed meal tolerance test (MMTT). Area under the curve (AUC) C-peptide and peak C-peptide were stratified by quartiles of expression of 31 miRNAs. After adjustment for baseline C-peptide, age, BMI, and sex, baseline levels of miR-3187-3p, miR-4302, and the miRNA combination of miR-3187-3p/miR-103a-3p predicted differences in MMTT C-peptide AUC/peak levels at the 12-month visit; the combination miR-3187-3p/miR-4723-5p predicted proportions of subjects above/below the 200 pmol/L clinical trial eligibility threshold at the 12-month visit. Thus, miRNA assessment at baseline identifies associations with C-peptide and stratifies subjects for future severity of C-peptide loss after 1 year. We suggest that miRNAs may be useful in predicting future C-peptide decline for improved subject stratification in clinical trials. 相似文献
134.
135.
Donald R. VanDevanter Sonya L. Heltshe Jay B. Hilliard Michael W. Konstan 《Journal of cystic fibrosis》2021,20(2):257-263
Background Antimicrobial susceptibility testing (AST) of bacterial isolates is a time- and resource-intensive procedure recommended by cystic fibrosis (CF) treatment guidelines for antimicrobial selection for pulmonary exacerbation (PEx) treatment.Methods We studied relationships between Pseudomonas aeruginosa (Pa) isolate AST results, antipseudomonal PEx treatments, and treatment responses as change in weight and percent predicted forced expiratory volume in 1 s (ppFEV1) as well as future antimicrobial treatment hazard for PEx occurring at a CF care center from 1999 through 2018. Treatments were categorized by “Pa coverage” as complete (all Pa isolates susceptible by AST to at least one administered agent), none (no isolates susceptible), incomplete (some, but not all isolates susceptible), and indeterminant (administered antipseudomonals not evaluated by AST). Weight and ppFEV1 responses were compared across Pa coverage categories using unadjusted and adjusted general estimating equations; hazard of future treatment was assessed by Cox and logistic regression.Results Among 3820 antimicrobial PEx treatment events in 413 patients with Pa, 62.6% (2390) had complete Pa coverage; 8.9% (340), 2.4% (99), and 26.2% (1000), had no, incomplete, and indeterminant Pa coverage, respectively. Mean baseline to follow-up weight change was +0.74 kg [95% CI 0.63, 0.86]; ppFEV1 change was +1.60 [1.29, 1.90]. Pa coverage category was not associated with significant differences in weight or ppFEV1 change or with future antimicrobial treatment hazard.Conclusions We did not observe superior responses for AST-defined complete Pa coverage treatments versus lesser coverage treatments, suggesting that AST may be of little utility in choosing antimicrobials for CF PEx treatment. 相似文献
136.
Dane Christina Daoud MD Elena M. S. Cartagena MD MSc Katherine J. P. Schwenger RD PhD Nicha Somlaw MD Leah Gramlich MD Scott Whittaker MD David Armstrong MD Brian Jurewitsch PharmD Matreyi Raman MD Donald R. Duerksen MD James D. McHattie MD Johane P. Allard MD 《JPEN. Journal of parenteral and enteral nutrition》2022,46(2):348-356
137.
Dominika Seidman Marielle Cavrois Joan F. Hilton Nadia R. Roan Sarah Averbach Margaret Takeda Eric Chang Nandhini Raman Ruth Greenblatt Barbara L. Shacklett Karen Smith-McCune 《Contraception》2021,103(1):44-47
IntroductionEx vivo fusion assays offer an efficient method for studying HIV-1 entry associated with contraceptive use and pregnancy outside of cohort studies of HIV-1 incidence.MethodsWe measured ex vivo HIV-1 fusion to cervical or endometrial immune cells from three groups of women: pregnant, non-pregnant not using hormonal or intrauterine contraception, and using depot medroxyprogesterone acetate (DMPA).Results and conclusionsThere was no excess susceptibility to HIV-1 fusion of cells from pregnant women or DMPA users compared to controls. Although the number of target cells in endometrium was higher in DMPA users compared to controls, HIV-1 fusion was lower.ImplicationsIn ex vivo assays, HIV-1 showed no enhanced fusion to cervical immune cells from pregnant women or DMPA users compared to controls, and lower fusion to endometrial immune cells from DMPA users. This assay is useful for studying hormonal and contraceptive effects on HIV-1 entry into reproductive tract immune cells. 相似文献
138.
Rebecca L. Brocato Steven A. Kwilas Matthew D. Josleyn Simon Long Xiankun Zeng Casey C. Perley Lucia M. Principe Brandon Somerville Melanie V. Cohen Jay W. Hooper 《Vaccine》2021,39(7):1101-1110
DNA vaccine evaluation in small animals is hampered by low immunogenicity when the vaccines are delivered using a needle and syringe. To overcome this technical hurdle we tested the possibility that a device developed for human intradermal medicine delivery might be adapted to successfully deliver a DNA vaccine to small animals. Disposable syringe jet injection (DSJI) does not currently exist for small animals. However, a commercialized, human intradermal device used to to administer medicines to the human dermis in a 0.1 mL volume was evaluated in Syrian hamsters. Here, we found that hantavirus DNA vaccines administered to hamsters using DSJI were substantially more immunogenic than the same vaccines delivered by needle/syringe or particle mediated epidermal delivery (gene gun) vaccination. By adjusting how the device was used we could deliver vaccine to either subcutaneous tissues, or through the skin into the muscle. RNA and/or antigen expression was detected in epidermal, subepidermal and fibroblast cells. We directly compared six optimized and non-optimized hantavirus DNA vaccines in hamsters. Optimization, including codon-usage and mRNA stability, did not necessarily result in increased immunogenicity for all vaccines tested; however, optimization of the Andes virus (ANDV) DNA vaccine protected vaccinated hamsters from lethal disease. This is the first time active vaccination with an ANDV DNA vaccine has shown protective efficacy in the hamster model. The adaptation of a human intradermal jet injection device for use as a method of subcutaneous and intramuscular jet injection of DNA vaccines will advance the development of nucleic acid based medical countermeasures for diseases modeled in hamsters. 相似文献
139.
A prospective study of the accuracy of preoperative computed tomographic staging of patients with biopsy-proven rectal carcinoma 总被引:3,自引:1,他引:2
Dr. Brenda Shank M.D. Ph.D. D. David Dershaw M.D. James Caravelli M.D. Jay Barth M.D. Warren Enker M.D. 《Diseases of the colon and rectum》1990,33(4):285-290
From June 1983 to January 1986, 91 patients with biopsy-proven adenocarcinoma of the rectum had computed tomographic scans of the pelvis performed before treatment as part of a "sandwich" radiotherapy-surgery regimen. Two experienced diagnostic radiologists performed locoregional staging of all scans according to the University of California at San Francisco criteria; one of these radiologists repeated this staging at a later time to test the reproducibility of a single observer. Staging was performed without the use of any other radiographic studies or of any clinical information except the patients' age, sex, and the diagnosis of rectal carcinoma, to test the value of computed tomographic scans alone for staging. Agreement between the two stagings performed by the first observer was 51 percent, and interobserver agreement was only 37 percent. Agreement with Dukes' staging was only 33 percent. Therefore, preoperative pelvic computed tomographic scanning of primary rectal adenocarcinoma should not be relied upon for staging or for the selection of patients for treatment options. 相似文献
140.